PAPP-A: a promising therapeutic target for healthy longevity.
PAPP-A: a promising therapeutic target for healthy longevity.
复制标题
DOI：
10.1111/acel.12564
复制
发表时间：
2017-04
期刊：
影响因子：
7.8
通讯作者：
Oxvig C
中科院分区：
文献类型：
--
作者：
Conover CA;Oxvig C
妊娠相关血浆蛋白A（PAPP-A）是一种蛋白水解酶，发现其通过切割抑制性胰岛素样生长因子（IGF）结合蛋白（IGFBPs）来增加局部IGF的可用性，从而激活受体。IGF信号的减少与寿命和健康寿命的增加有关。因此，抑制PAPP-A代表了间接降低生物活性IGF可用性的新方法。在这里，我们将回顾支持PAPP-A作为促进健康长寿的治疗靶点的数据。
Pregnancy‐associated plasma protein‐A (PAPP‐A) is a proteolytic enzyme that was discovered to increase local insulin‐like growth factor (IGF) availability for receptor activation through cleavage of inhibitory IGF binding proteins (IGFBPs). Reduced IGF signaling has been associated with increased lifespan and healthspan. Therefore, inhibition of PAPP‐A represents a novel approach to indirectly decrease the availability of bioactive IGF. Here, we will review data in support of PAPP‐A as a therapeutic target to promote healthy longevity.